NewsBenzingaAtara Biotherapeutics’ Partner Pierre Fabre Pharmaceuticals erhält FDA-Zulassung zur erneuten Einreichung des Biologics License Application für Tabelecleucel zur Behandlung der Epstein-Barr-Virus-positiven posttransplantationsbedingten... Atara Biotherapeutics’ Partner Pierre Fabre Pharmaceuticals erhält FDA-Zulassung zur erneuten Einreichung des Biologics License Application für Tabelecleucel zur Behandlung der Epstein-Barr-Virus-positiven posttransplantationsbedingten... Benzinga 2026.10.14 12:08 (GMT+0) Open on Benzinga Other news If Apple Cuts iPhone Units in 2027, This Stock Could Be a Big Loser Trust company AnchorWatch Trust Company launches Bitcoin custody service Wells Fargo Maintains Equal-Weight on PENN Entertainment, Lowers Price Target to $22 HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target Alphabet Stock Rises: What's Going On? $1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today
